Q-omics provides the consensus-scored ZNF697 profile across patient tissues and cancer cell-line models. ZNF697 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF697 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZNF697 RNA expression shows 19,243 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where ZNF697 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF697 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF697 survival associations across molecular data types. ZNF697 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF697 RNA expression–survival associations across cancer types. High ZNF697 expression shows unfavorable associations in LIHC, LUAD, READ and CESC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF697 RNA expression.
This table summarizes ZNF697 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF697. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF697 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, COAD, BLCA and STAD. The HNSC box plot shows higher ZNF697 RNA expression in tumor versus normal tissue (log2 FC = +1.853, t-test p < 0.001).
This table shows molecular features associated with ZNF697 in patient tissues and cancer cell lines. In patient samples, ZNF697 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF697 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
